# KFF (Kaiser Family Foundation)

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/kff-kaiser-family-foundation
Canonical HTML page: https://getbiobrief.com/entity/kff-kaiser-family-foundation

## Timeline

- **2026-04**: Pfizer-Valneva regulatory submission planned — Pfizer and Valneva announce they intend to file for approval of their Lyme disease vaccine candidate this spring, according to KFF Health News.
- **2002-02**: LYMErix withdrawn from market — Citing low demand, lawsuits alleging side effects, and mounting public mistrust, the manufacturer pulls the vaccine only three years after launch.
- **1998-12**: FDA approves LYMErix — SmithKline Beecham (now GSK) receives approval for the first Lyme disease vaccine, aimed at preventing the tick-borne illness.

## Recent coverage (1 stories)

### Pfizer-Valneva Lyme Vaccine Targets 476K Annual Cases, But Uptake Uncertain
2026-08-07 07:55:48 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Pfizer and Valneva’s planned regulatory submission for a new Lyme disease vaccine enters a market haunted by the failure of LYMErix and amplified vaccine skepticism, challenging the blockbuster potential of a shot aimed at 476,000 annual U.S. cases.
Full story: https://getbiobrief.com/story/pfizer-valneva-lyme-vaccine-bio-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.